DJI46,980.80+0.91%
GDAXI23,564.01+0.50%
GSPC6,707.67+1.14%
HSI25,834.02+1.45%
IXIC22,420.78+1.43%
N22553,751.15-0.13%
AAPL252.90+1.11%
AMZN211.01+1.61%
CL93.55-5.23%
EURUSD1.1525+0.89%
GBPUSD1.3333+0.83%
GC5,003.50-1.15%
GOOG303.66+0.73%
JPM285.78+0.83%
META626.90+2.24%
MSFT398.92+0.85%
NVDA184.92+2.59%
TSLA398.11+1.77%
DJI46,980.80+0.91%
GDAXI23,564.01+0.50%
GSPC6,707.67+1.14%
HSI25,834.02+1.45%
IXIC22,420.78+1.43%
N22553,751.15-0.13%
AAPL252.90+1.11%
AMZN211.01+1.61%
CL93.55-5.23%
EURUSD1.1525+0.89%
GBPUSD1.3333+0.83%
GC5,003.50-1.15%
GOOG303.66+0.73%
JPM285.78+0.83%
META626.90+2.24%
MSFT398.92+0.85%
NVDA184.92+2.59%
TSLA398.11+1.77%
DJI46,980.80+0.91%
GDAXI23,564.01+0.50%
GSPC6,707.67+1.14%
HSI25,834.02+1.45%
IXIC22,420.78+1.43%
N22553,751.15-0.13%
AAPL252.90+1.11%
AMZN211.01+1.61%
CL93.55-5.23%
EURUSD1.1525+0.89%
GBPUSD1.3333+0.83%
GC5,003.50-1.15%
GOOG303.66+0.73%
JPM285.78+0.83%
META626.90+2.24%
MSFT398.92+0.85%
NVDA184.92+2.59%
TSLA398.11+1.77%
CYBERETIKAGLOBAL FINANCIAL INTELLIGENCE
LIVE
USA Seeking Alpha EN

Savara GAAP EPS of -$0.13

Mar 13, 2026 &03281313202631; 19:28 UTC seekingalpha.com Trending 2/5
Read original on seekingalpha.com ↗
↘
Negative for markets
Sentiment score: -65/100
Moderate impact Short-term (days)
WHAT THIS MEANS
Savara Inc. reported a GAAP EPS of -$0.13, indicating continued operating losses and negative earnings per share. This reflects ongoing cash burn typical of clinical-stage biopharmaceutical companies with limited revenue generation.
AI CONFIDENCE
75% High
SENTIMENT GAUGE
NEWS POWER SCORE
AFFECTED ASSETS
↓
SVRA
SVRAStock
Expected to decline
Negative EPS of -$0.13 demonstrates ongoing losses and cash burn, typical pressure point for biotech stocks without approved revenue-generating products
PRICE HISTORY
Loading chart...
⚡ SUGGESTED ACTION
Avoid or reduce positions in SVRA until clinical trial data demonstrates meaningful progress toward FDA approval or revenue generation. Monitor cash runway and upcoming trial results as key catalysts for potential recovery.
KEY SIGNALS
Negative earnings per shareOperating losses continuingCash burn concerns for clinical-stage biotechNo near-term profitability visible
SECTORS INVOLVED
HealthcareBiotechnologyPharmaceuticals
Analysis generated on Mar 16, 2026 at 13:22 UTC
Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

RELATED INTELLIGENCE

Middle East oil exports drop at least 60% as Strait of Hormuz stays mostly closed, data shows
BNN Bloomberg Mar 16, 21:13 Negative
Bell plans $1.7B AI data centre in Saskatchewan as demand for computing power surges
BNN Bloomberg Mar 16, 21:03 Positive
Urbana Corporation Intersects 4.2 g/t Au over 10 Metres and Begins Second Drill Program
BNN Bloomberg Mar 16, 20:59 Positive
Surging gas prices threaten to reverse Canada’s inflation progress, economists say
BNN Bloomberg Mar 16, 20:46 Negative
Market Outlook: Iran conflict and oil surge raise stakes before U.S. Fed
BNN Bloomberg Mar 16, 20:43 Negative